Pure Global AI
NCT06414720Recruiting

Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study
University of UdineClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Endometriosis
Drug/Device/Intervention
Dienogest 2 MG
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
University of Udine
Location
Udine, Italy
Timeline & enrollment
Phase
N/A
Start date
Apr 22, 2024
End date
May 01, 2025
Enrollment
90 participants
Primary outcome

response to the progestin therapy,changes in quality of life,differences in salivary miRNoma

Summary

This study aims to analyze the salivary miRNA specific for patients diagnosed with
 endometriosis, specifically evaluating the miRNA profile of patients who respond versus those
 who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain
 Clinic will be recruited, and they will be asked to provide a saliva sample before starting
 medical therapy. The response to the therapy will be evaluated after 4 months from the
 beginning of the therapy itself.

ICD-10 classifications
EndometriosisOther endometriosisEndometriosis, unspecifiedEndometriosis of uterusEndometriosis of ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414720
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414720 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Udine and is currently Recruiting. The study focuses on Endometriosis. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.